



**Systematics of the genus *Candida*;
implications for understanding clinical
presentation, mixed infection and antifungal
treatment and the influence on strain maintenance
and replacement during oral candidiasis in HIV-
infected individuals**

A thesis presented for the degree of

Doctor of Philosophy

by

Michelle Fraser BSc Hons (Micro. and Dent.)

at

Adelaide University

South Australia

8th July, 2002

Abstract

Oropharyngeal candidiasis is an opportunistic infection associated with immunocompromisation. Despite recent reports of a decline in the prevalence of this oral infection with HAART (highly-active antiretroviral therapy) treatment of HIV infection, it continues to be a significant cause of morbidity in this patient group. There have been numerous studies investigating the epidemiology of *Candida* infection and the taxonomic structure of the genus. This study assesses the systematics (ie., taxonomy, phylogeny and epidemiology) of thirteen *Candida* species of medical importance using type and reference strains plus isolates obtained from 101 HIV-positive individuals and 20 HIV-negative asymptomatic carriers. The techniques used were allozyme electrophoresis at 15-20 independent enzyme loci and sequence comparisons within the 16S, ITS1, ITS2 and 5.8S rRNA regions. The results of this study have confirmed the existence of a number of distinct species but, as previous studies have also reported, questions the validity of the genus *Candida*. This conclusion is made on the basis of the extent of genetic variation observed between *Candida* species and the close relationships between some *Candida* species and species of other fungal genera. Of epidemiological significance, the study supports the theory that oropharyngeal candidiasis is opportunistic with isolates from HIV-positive patients being genetically interspersed with isolates from asymptomatic carriers. Additionally, the strain infecting a patient changes as frequently as weekly, many patients are co-colonised by multiple strains and different strains can be isolated from multiple concurrent lesions. Whilst the results of this study have not resolved many of the epidemiological and taxonomic issues still under debate, they have provided a comprehensive framework that can be used to build our understanding of the complex interactions between strains of *Candida*, antifungal therapy, HIV treatment, the immune response and the oral cavity.

1 INTRODUCTION..... 1

- 1.1 The Kingdom Fungi - taxonomy and phylogeny..... 2**
 - 1.1.1 Definitions4
 - 1.1.2 The importance of accurately identifying organisms5
 - 1.1.3 Fungal phyla.....7
 - 1.1.4 Ascomycota.....8

- 1.2 The genus *Candida* (Berkhout)..... 10**
 - 1.2.1 Morphology and biochemistry of the genus11
 - 1.2.2 Genetic characteristics of the genus.....13
 - 1.2.3 Medically-relevant species14
 - 1.2.4 Pathogenicity factors within the genus *Candida*.....24
 - 1.2.5 Mechanisms of antifungal resistance in *Candida*.....27

- 1.3 *Candida* infection..... 28**
 - 1.3.1 The immune response to *Candida* infection28
 - 1.3.2 Epidemiology of infection.....30
 - 1.3.2.a Oropharyngeal *Candida* infections 31
 - 1.3.2.b Gastrointestinal candidiasis 39
 - 1.3.2.c Vaginal candidiasis..... 40
 - 1.3.2.d Candiduria 41
 - 1.3.2.e Systemic and disseminated *Candida* infections..... 42

- 1.4 Aims 44**
 - 1.4.1 Specific Aim 45
 - 1.4.2 Rationale..... 45
 - 1.4.3 Specific objectives..... 46

2 GENERAL MATERIALS AND METHODS 47

2.1	<i>Sample collection, growth and preparation</i>	48
2.1.1	<i>Type and reference strains of Candida and related genera</i>	48
2.1.2	<i>Non-Candida fungal species of clinical relevance</i>	48
2.1.2.a	<i>Saccharomyces cerevisiae</i> Meyen ex Hansen.....	50
2.1.2.b	<i>Cryptococcus neoformans</i> (Sanfelice) Vuillemin.....	50
2.1.2.c	<i>Trichosporon beigellii</i> (Kuchenmeister & Rabenhorst) Vuillemin.....	51
2.1.3	<i>Candida clinical sample collection and culturing</i>	51
2.1.4	<i>Sonication and cell lysate preparation for allozyme electrophoresis</i>	53
2.1.5	<i>DNA preparation</i>	53
2.2	<i>Techniques</i>	54
2.2.1	<i>Traditional identification techniques</i>	54
2.2.2	<i>Allozyme electrophoresis</i>	54
2.2.2.a	Electrophoresis and histochemical staining methods.....	55
2.2.2.b	Analytical methods.....	57
2.2.3	<i>Molecular biological methods</i>	59
2.2.3.a	18S ribosomal RNA sequencing.....	59
2.2.3.b	5.8S ribosomal RNA and flanking region sequencing.....	59
2.2.3.c	Sequencing methods	60
2.2.3.d	Analysis programs	60

3 RESULTS AND INTERPRETATIONS..... 65

3.1	<i>Evaluation and optimisation of allozyme electrophoresis for taxonomy and epidemiology.....</i>	65
3.1.1	<i>Pilot screen</i>	67
3.1.1.a	Background	67
3.1.1.b	Materials and methods.....	67
3.1.1.c	Results	68
3.1.1.d	Interpretation	74
3.1.2	<i>Pilot Study 1.....</i>	74
3.1.2.a	Background	74
3.1.2.b	Materials and methods.....	75
3.1.2.c	Results	76
3.1.2.d	Interpretation	82
3.1.3	<i>Pilot Study 2.....</i>	83
3.1.3.a	Background	83
3.1.3.b	Materials and Methods	83
3.1.3.c	Results	84
3.1.3.d	Interpretation	88
3.1.4	<i>Detection of reference strain contamination</i>	89
3.1.4.a	Background	89
3.1.4.b	Materials and Methods	89
3.1.4.c	Results	90
3.1.4.d	Interpretation	90
3.1.5	<i>General Interpretation of preliminary investigations</i>	90
3.2	<i>Taxonomic analyses using allozyme electrophoresis</i>	93
3.2.1	<i>Type and reference strain relationships</i>	93
3.2.1.a	Background	93
3.2.1.b	Materials and methods.....	94
3.2.1.c	Results	94
3.2.1.d	Interpretation	99
3.2.2	<i>Genetic characterization of phenotypically diverse Candida clinical isolates.....</i>	100
3.2.2.a	Background	100
3.2.2.b	Material and methods	101
3.2.2.c	Results	101
3.2.2.d	Interpretation	108
3.2.3	<i>General Interpretation.....</i>	108

3.3 Epidemiological analyses of isolates from HIV-positive patients using allozyme electrophoresis 110

3.3.1 Background..... 110

3.3.2 General materials and methods..... 110

3.3.3 Study 1 111

3.3.3.a Results 111

3.3.3.b Interpretation 118

3.3.4 Study 2 118

3.3.4.a Results 118

3.3.4.b Interpretation 124

3.3.5 Study 3 124

3.3.5.a Results 124

3.3.5.b Interpretation 129

3.3.6 Study 4 130

3.3.6.a Results 130

3.3.6.b Interpretation 137

3.3.7 Study 5 139

3.3.7.a Results 139

3.3.7.b Interpretation 144

3.3.8 Study 6 145

3.3.8.a Results 145

3.3.8.b Interpretation 152

3.3.9 Study 7 155

3.3.9.a Results 155

3.3.9.b Interpretation 162

3.3.10 Study 8 164

3.3.10.a Results 164

3.3.10.b Interpretation 171

3.3.11 Study 9 173

3.3.11.a Results 173

3.3.11.b Interpretation 181

3.3.12 Study 10 184

3.3.12.a Results 184

3.3.12.b Interpretation 191

3.3.13 Study 11 193

3.3.13.a Results 193

3.3.13.b Interpretation 197

3.3.14 General Results and Interpretation 197

3.4 Summary of allozyme electrophoresis studies 198

3.5	<i>Phylogenetic analyses using 18S ribosomal RNA</i>	200
3.5.1	<i>General Background</i>	200
3.5.2	<i>Phylogenetic evaluation using the complete 18S rRNA sequence</i>	201
3.5.2.a	Materials and methods	201
3.5.2.b	Results	201
3.5.2.c	Interpretation	206
3.5.3	<i>Identification of a 490-bp species-diagnostic sequence</i>	206
3.5.3.a	Background	206
3.5.3.b	Materials and methods	207
3.5.3.c	Results	207
3.5.3.d	Interpretation	224
3.6	<i>Genetic analyses using ITS1, 5.8S rRNA, ITS2 sequences</i>	225
3.6.1	<i>Epidemiological utility of 5.8S rRNA, ITS1 and ITS2 sequences</i>	225
3.6.1.a	Background	225
3.6.1.b	Materials and methods	225
3.6.1.c	Results	226
3.6.1.d	Interpretation	239
3.6.2	<i>Phylogenetic utility of the ITS2 region</i>	239
3.6.2.a	Results	239
3.6.2.b	Interpretation	240

4	DISCUSSION	254
4.1	<i>Restatement of Aim</i>	<i>254</i>
4.2	<i>Epidemiology of oral Candida colonisation.....</i>	<i>254</i>
4.2.1	<i>Strain variability.....</i>	<i>255</i>
4.2.2	<i>Phenotypic observations.....</i>	<i>259</i>
4.2.3	<i>HIV status</i>	<i>260</i>
4.2.4	<i>Clinical presentation</i>	<i>261</i>
4.2.5	<i>Antifungal treatment.....</i>	<i>263</i>
4.3	<i>Taxonomy of Candida and related genera.....</i>	<i>266</i>
4.4	<i>Future directions</i>	<i>272</i>
4.5	<i>Summary.....</i>	<i>275</i>
5	REFERENCES	276